Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.31 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.31 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15232657 | 0.78 | — | — | |
| SCHEMBL477423 | 0.76 | HDAC4 (0.38) | CYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL4731891 | 0.74 | HDAC4 (0.37) | CYP1A2TSHR | |
| SCHEMBL23799317 | 0.74 | KDM4E (0.62) | KDM4EKMT2A | |
| SCHEMBL29384604 | 0.73 | KDM4E (0.50) | KDM4EKMT2AOPRM1CYP1A2CYP2D6 | |
| SCHEMBL1710564 | 0.73 | KDM4E (0.41) | KDM4EKMT2AOPRM1CYP1A2CYP2D6 | |
| SCHEMBL6837847 | 0.72 | HDAC8 (0.39) | KDM4EKMT2ACYP2D6HDAC1TSHR | |
| SCHEMBL21856103 | 0.72 | OPRM1 (0.38) | KDM4EKMT2AOPRM1CYP1A2NPFFR1 | |
| Hydrochloric Acid SCHEMBL17748973 | 0.71 | KDM4E (0.39) | KDM4EKMT2AOPRM1CYP1A2GABRD | |
| SCHEMBL4725793 | 0.70 | KDM4E (0.34) | KDM4EKMT2AOPRM1NPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208604-B2 | Methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT INC. (US) | 2007-04-24 | — | — | US | claimed |
| EP-1246801-B1 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC (US) | 2006-09-20 | — | — | EP | claimed |
| US-7074935-B2 | Methods for the syntheses of alfentanil, sufentanil and remifentanil | MALLINCKRODT INC. (US) | 2006-07-11 | — | — | US | claimed |
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT, INC. | 2006-07-06 | — | — | US | claimed |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | MALLINCKRODT, INC. | 2004-07-15 | — | — | US | claimed |
| EP-1246801-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001040184-B1 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC (US) | 2002-01-31 | — | — | WO | claimed |
| WO-2001040184-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2001-06-07 | — | — | WO | claimed |
| EP-0721452-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | Mallinckrodt Chemical, Inc. (US) | 1996-07-17 | — | — | EP | claimed |
| US-5489689-A | CONDENSING A PIPERIDONE WITH A PRIMARY AMINE TO FORM A 4-AMINO-4-CARBOXYAMINOPIPERIDINE; HYDROLYSIS; CONDENSATION WITH A MESYLATE CONTAINING A PHENYL, THIENYL OR 4-ETHYL-4,5-DIHYDRO-5-OXO-1H-TETRAZPINE | MALLINCKRODT CHEMICAL, INC. (US) | 1996-02-06 | — | — | US | claimed |
| WO-1995009152-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | MALLINCKRODT CHEMICAL, INC. (US) | 1995-04-06 | — | — | WO | claimed |
| EP-2616464-B1 | IMPROVED PROCESS FOR THE PREPARATION OF A PRECURSOR OF SUFENTANIL BASE | MALLINCKRODT LLC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-8946433-B2 | Process for the preparation of sufentanil base and related compounds | MALLINCKRODT LLC (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2455377-B1 | Synthesis of fentanyl analogs | HAMELN RDS GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2616464-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | Mallinckrodt LLC (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2001040184-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0721452-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | Mallinckrodt Chemical, Inc. (US) | 1996-07-17 | — | — | EP | disclosed |
| US-5489689-A | CONDENSING A PIPERIDONE WITH A PRIMARY AMINE TO FORM A 4-AMINO-4-CARBOXYAMINOPIPERIDINE; HYDROLYSIS; CONDENSATION WITH A MESYLATE CONTAINING A PHENYL, THIENYL OR 4-ETHYL-4,5-DIHYDRO-5-OXO-1H-TETRAZPINE | MALLINCKRODT CHEMICAL, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| US-5489689-A | CONDENSING A PIPERIDONE WITH A PRIMARY AMINE TO FORM A 4-AMINO-4-CARBOXYAMINOPIPERIDINE; HYDROLYSIS; CONDENSATION WITH A MESYLATE CONTAINING A PHENYL, THIENYL OR 4-ETHYL-4,5-DIHYDRO-5-OXO-1H-TETRAZPINE | MALLINCKRODT CHEMICAL, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995009152-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | MALLINCKRODT CHEMICAL, INC. (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | OPRK1, OPRM1, OPRL1 | KDM4E 1420/4885KMT2A 577/4885DPP9 3598/4885 |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | HNMT, OPRM1, ALKBH3 | KDM4E 153/4885KMT2A 91/4885DPP9 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.